Delivering non-hormonal contraceptives to men: advances and obstacles

Trends in Biotechnology

Volumn 26, Issue 2, 2008, Pages 90-99

  Mruk, Dolores D ^a   Yan Cheng, C ^a  

^a POPULATION COUNCIL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVES; THERAPEUTIC COMPOUNDS;

BIOLOGICAL ORGANS; BIOMEDICAL ENGINEERING; HORMONES; METABOLISM; PATIENT TREATMENT; TOXICITY;

DRUG DELIVERY;

1 (2,4 DICHLOROBENZYL) 1H INDAZOLE 3 CARBOHYDRAZIDE; ADJUDIN; AF 2364; ANTISPERMATOGENIC AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARBOXYLIC ACID DERIVATIVE; FOLLITROPIN; GELATINASE B; LONIDAMINE; MALE CONTRACEPTIVE AGENT; METHYLTESTOSTERONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; NATRIURETIC PEPTIDE TYPE C; RHO KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZOSUQUIDAR;

BIOTECHNOLOGY; BLOOD TESTIS BARRIER; COMPLEX FORMATION; CONTRACEPTION; DESMOSOME; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TRANSPORT; EXTRACELLULAR MATRIX; GERM CELL; HEPATITIS; HUMAN; HYPOPHYSIS; LIVER TOXICITY; MALE GENITAL SYSTEM; MEDICAL RESEARCH; MEN'S HEALTH; METABOLIC CLEARANCE RATE; MICROVASCULATURE; MUSCLE ATROPHY; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SERTOLI CELL; TESTIS; TIGHT JUNCTION;

CONTRACEPTIVE AGENTS, MALE; DRUG DELIVERY SYSTEMS; FORECASTING; HORMONES; HUMANS; MEN;

EID: 38349148676     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2007.10.009     Document Type: Review

References (75)

1. Anderson R.A., and Baird D.T. Male contraception. Endocr. Rev. 23 (2002) 735-762
2. Kamischke A., and Nieschlag E. Progress towards hormonal male contraception. Trends Pharmacol. Sci. 25 (2004) 49-57
3. Coutinho E.M. Gossypol: a contraceptive for men. Contraception 65 (2002) 259-263
4. Waites G.M., et al. Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. Int. J. Androl. 21 (1998) 8-12
5. Qian S.Z. Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception 36 (1987) 335-345
6. Lopez L.M., et al. Nonhormonal drugs for contraception in men: a systematic review. Obstet. Gynecol. Surv. 60 (2005) 746-752
7. Cheng C.Y., and Mruk D.D. Cell junction dynamics in the testis: Sertoli-germ cell interactions and male contraceptive development. Physiol. Rev. 82 (2002) 825-874
8. van der Spoel A.C., et al. Reversible infertility in male mice after oral administration of alkylated imino sugars: a hormonal approach to male contraception. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 17173-17178
9. Amory J.K., et al. Miglustat has no apparent effect on spermatogenesis in normal men. Hum. Reprod. 22 (2007) 702-707
10. Naz R.K. Antisperm immunity for contraception. J. Androl. 27 (2006) 153-159
11. Suri A. Contraceptive vaccines targeting sperm. Expert Opin. Biol. Ther. 5 (2005) 381-392
12. Cheng C.Y., et al. AF-2364 [1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide] is a potential male contraceptive: a review of recent data. Contraception 72 (2005) 251-261
13. Mruk D.D., and Cheng C.Y. Sertoli-Sertoli and Sertoli-germ cell interactions and their significance in germ cell movement in the seminiferous epithelium during spermatogenesis. Endocr. Rev. 25 (2004) 747-806
14. Jegou B. The Sertoli-germ cell communication network in mammals. Int. Rev. Cytol. 147 (1993) 25-96
15. Jegou B. The Sertoli cell in vivo and in vitro. Cell Biol. Toxicol. 8 (1992) 49-54
16. Boekelheide K. Sertoli cell toxicants. In: Russell L., and Griswold M. (Eds). The Sertoli Cell (1993), Cache River Press, Clearwater 551-575
17. Silvestrini B., et al. Lonidamine and related compounds. Prog. Med. Chem. 21 (1984) 110-135
18. Cheng C.Y., et al. Two new male contraceptives exert their effects by depleting germ cells prematurely from the testis. Biol. Reprod. 65 (2001) 449-461
19. Chen Y.M., et al. Fer kinase/Fer T and adherens junction dynamics in the testis: an in vitro and in vivo study. Biol. Reprod. 69 (2003) 656-672
20. Grima J., et al. Reversible inhibition of spermatogenesis in rats using a new male contraceptive, 1-(2,4-dichlorobenzyl)-indazole-3-carbohydrazide. Biol. Reprod. 64 (2001) 1500-1508
21. Mruk D.D., et al. A male contraceptive targeting germ cell adhesion. Nat. Med. 12 (2006) 1323-1328
22. Hild S.A., et al. Disruption of spermatogenesis and Sertoli cell structure and function by the indenopyridine CDB-4022 in rats. Biol. Reprod. 65 (2001) 1771-1779
23. Hild S.A., et al. Acute adverse effects of the indenopyridine CDB-4022 on the ultrastructure of Sertoli cells, spermatocytes, and spermatids in rat testes: Comparison to the known Sertoli cell toxicant di-n-pentylphthalate (DPP). J. Androl. 28 (2007) 621-629
24. Hild S.A., et al. Development of l-CDB-4022 as a nonsteroidal male oral contraceptive: Induction and recovery from severe oligospermia in the adult male cynomolgus monkey (Macaca fascicularis). Endocrinology 148 (2007) 1784-1796
25. Hild S.A., et al. Lupron Depot prevention of antispermatogenic/antifertility activity of the indenopyridine, CDB-4022, in the rat. Biol. Reprod. 65 (2001) 165-172
26. Vogl A.W., et al. Unique and multifunctional adhesion junctions in the testis: ectoplasmic specializations. Arch. Histol. Cytol. 63 (2000) 1-15
27. Yan H.H.N., et al. Ectoplasmic specialization: a friend or a foe of spermatogenesis?. Bioessays 29 (2007) 36-48
28. Siu M.K.Y., and Cheng C.Y. Dynamic cross-talk between cells and the extracellular matrix in the testis. Bioessays 26 (2004) 978-992
29. Wolski K.M., et al. Strength measurement of the Sertoli-spermatid junctional complex. J. Androl. 26 (2005) 354-359
30. Wolski K.M., et al. The Sertoli-spermatid junctional complex adhesion strength is affected in vitro by adjudin. J. Androl. 27 (2006) 790-794
31. Russell L. Movement of spermatocytes from the basal to the adluminal compartment of the rat testis. Am. J. Anat. 148 (1977) 313-328
32. Lui W.Y., et al. TGF-β3 regulates the blood-testis barrier dynamics via the p38 mitogen activated protein (MAP) kinase pathway: an in vivo study. Endocrinology 144 (2003) 1139-1142
33. Xia W., et al. Differential interactions between transforming growth factor-β3/TßR1, TAB1, and CD2AP disrupt blood-testis barrier and Sertoli-germ cell adhesion. J. Biol. Chem. 281 (2006) 16799-16813
34. Siu M.K.Y., et al. The interplay of collagen IV, tumor necrosis factor-α, gelatinase B (matrix metalloprotease-9), and tissue inhibitor of metalloprotease-1 in the basal lamina regulates Sertoli cell-tight junction dynamics in the rat testis. Endocrinology 144 (2003) 371-387
35. Li M.W.M., et al. Tumor necrosis factor α reversibly disrupts the blood-testis barrier and impairs Sertoli-germ cell adhesion in the seminiferous epithelium of adult rat testes. J. Endocrinol. 190 (2006) 313-329
36. Xia W., et al. C-type natriuretic peptide regulates blood-testis barrier dynamics in adult rat testes. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3841-3846
37. Xia W., and Cheng C.Y. TGF-β3 regulates anchoring junction dynamics in the seminiferous epithelium of the rat testis via the Ras/ERK signaling pathway: an in vivo study. Dev. Biol. 280 (2005) 321-343
38. Wong C.H., et al. Regulation of blood-testis barrier dynamics: an in vivo study. J. Cell Sci. 117 (2004) 783-798
39. Janecki A., et al. Effect of cadmium chloride on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment cultures - a new model for toxicological investigations of the 'blood-testis' barrier in vitro. Toxicol. Appl. Pharmacol. 112 (1992) 51-57
40. Chung N.P.Y., and Cheng C.Y. Is cadmium chloride-induced inter-Sertoli tight junction permeability barrier disruption a suitable in vitro model to study the events of junction disassembly during spermatogenesis in the rat testis?. Endocrinology 142 (2001) 1878-1888
41. Meng J., et al. Androgen regulates the permeability of the blood-testis barrier. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16696-16700
42. Wang R.S., et al. Androgen receptor in Sertoli cell is essential for germ cell nursery and junctional complex formation in mouse testes. Endocrinology 147 (2006) 5624-5633
43. Yan, H.H.N. et al. Blood-testis barrier dynamics are regulated by testosterone and cytokines via their differential effects on the kinetics of protein endocytosis and recycling in Sertoli cells. FASEB J. (in press)
44. Leslie E.M., et al. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2 and BRCP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 (2005) 216-237
45. Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25 (2004) 423-429
46. Melaine N., et al. Multidrug resistance genes and p-glycoprotein in the testis of the rat, mouse, guinea pig, and human. Biol. Reprod. 67 (2002) 1699-1707
47. Bart J., et al. The distribution of drug-efflux pumps, Pgp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur. J. Cancer 40 (2004) 2064-2070
48. Van Asperen J., et al. Altered pharmacokinetics of vinblastine in mdr 1a P-glycoprotein deficient mice. J. Natl. Cancer Inst. 88 (1996) 994-999
49. Schinkel A.H., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
50. Schinkel A.H., et al. Absence of the mdrl1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Invest. 96 (1995) 1698-1705
51. Choo E.F., et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testis. Drug Metab. Dispos. 28 (2000) 655-660
52. Setchell, B.P. Blood-testis barrier, junctional and transport proteins and spermatogenesis. In Molecular Mechanisms in Spermatogenesis (Cheng, C.Y., ed.), Landes Bioscience (in press)
53. Griswold M.D., et al. The molecular biology of the FSH receptor. J. Steroid Biochem. Mol. Biol. 53 (1995) 215-218
54. Rose M.P., et al. Definition and measurement of follicle stimulating hormone. Endocr. Rev. 21 (2000) 5-21
55. Bishop L.A., et al. Both of the β-subunit carbohydrate residues of follicle-stimulating hormone determine the metabolic clearance rate and in vivo potency. Endocrinology 136 (1995) 2635-2640
56. Bishop L.A., et al. Specific roles for the asparagine-linked carbohydrate residues of recombinant human follicle stimulating hormone in receptor binding and signal transduction. Mol. Endocrinol. 8 (1994) 722-731
57. Flack M.R., et al. Site-directed mutagenesis defines the individual roles of the glycosylation sites on follicle-stimulating hormone. J. Biol. Chem. 269 (1994) 14015-14020
58. Valove F.M., et al. Receptor binding and signal transduction are dissociable functions requiring different sites on follicle-stimulating hormone. Endocrinology 135 (1994) 2657-2661
59. Blithe D.L., and Iles R.K. The role of glycosylation in regulating the glycoprotein hormone free α-subunit and free β-subunit combination in the extraembryonic coelomic fluid of early pregnancy. Endocrinology 136 (1995) 903-910
60. Thotakura N.R., and Blithe D.L. Glycoprotein hormones: glycobiology of gonadotrophins, thyrotrophin and free α subunit. Glycobiology 5 (1995) 3-10
61. Chien Y.W., et al. Nasal Systemic Drug Delivery (1989), Marcel Dekker
62. Gupta B., et al. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57 (2005) 637-651
63. Donovan M.D., et al. Absorption of polyethylene glycols 600 through 2000: The molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 7 (2000) 863-868
64. Sarkar M.A. Drug metabolism in the nasal mucosa. Pharm. Res. 9 (1992) 1-9
65. Ugwoke M.I., et al. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 53 (2001) 3-21
66. Schipper N.G.M., et al. The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm. Res. 8 (1991) 807-814
67. Ugwoke M.I., et al. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 57 (2005) 1640-1665
68. Sinswat P., and Tengamnuay P. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: Comparison with hydroxypropyl- and dimethyl-β-cyclodextrins. Int. J. Pharm. 257 (2003) 15-22
69. Soane R.J., et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 178 (1999) 55-65
70. von Eckardstein S., et al. A clinical trial of 7α-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J. Clin. Endocrinol. Metab. 88 (2003) 5232-5239
71. Kim M.K., et al. Formulation of a reservoir-type testosterone transdermal delivery system. Int. J. Pharm. 219 (2001) 51-59
72. Singh A.B., et al. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 91 (2006) 136-144
73. Turner T.T., et al. Testicular microvascular blood flow: alteration after Leydig cell eradication and ischemia but not experimental varicocele. J. Androl. 17 (1996) 239-248
74. Ohtsuka A. Microvascular architecture of the pampiniform plexus-testicular artery system in the rat: a scanning electron microscope study of corrosion casts. Am. J. Anat. 169 (1984) 285-293
75. Stachowiak J.C., et al. Piezoelectric control of needle-free transdermal drug delivery. J. Control Release 124 (2007) 88-97